Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 10—October 2014
Research

Effects of Mefloquine Use on Plasmodium vivax Multidrug Resistance

Nimol Khim, Voahangy Andrianaranjaka, Jean Popovici, Saorin Kim, Arsene Ratsimbasoa, Christophe Benedet, Celine Barnadas, Remy Durand, Marc Thellier, Eric Legrand, Lise Musset, Michela Menegon, Carlo Severini, Bakri Y.M. Nour, Magali Tichit, Christiane Bouchier, Odile Mercereau-Puijalon, and Didier MénardComments to Author 
Author affiliations: Institut Pasteur, Phnom Penh, Cambodia (N. Khim, J. Popovici, S. Kim, C. Benedet, D. Ménard); Institut Pasteur, Antananarivo, Madagascar (V. Andrianaranjaka); Université d’Antananarivo, Antananarivo (A. Ratsimbasoa); Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia (C. Barnadas); University of Melbourne, Melbourne (C. Barnadas); Hôpital Avicenne, Bobigny, France (R. Durand); Centre Hospitalier Universitaire Pitié Salpetrière, Paris, France (M. Thellier); Institut Pasteur, Cayenne, French Guiana (E. Legrand, L. Musset); Istituto Superiore di Sanità (ISS), Rome, Italy (M. Menegon, C. Severini); University of Gezira, Wad Medani, Sudan (B.Y.M. Nour); Institut Pasteur, Paris (M. Tichit, C. Bouchier, O. Mercereau-Puijalon)

Main Article

Table 3

Variation in number of copies of Plasmodium vivax mdr-1 gene in isolates from residents of selected Asian and African countries

Variable Country, years of sample collection
 Total p value
French Guiana, 2000–2003 Cambodia, 2010 Madagascar, 2006–2007 Sudan, 2007
No. isolates 117 117 199 59 492
Isolates with >1 Pvmdr-1 copy
No. (%; 95% CI) 69 (59; 46–75) 37 (32; 23–45) 2 (1; 0.1–3.6) 1 (2; 0.4–9.5) 109 (22; 18–26) <10–10*
Range 1–5 1–4 1–2 1–2 1–5
Copies, no. (%) <10–10*
1 48 (41) 80 (67) 198 (99) 57 (98) 383 (77.9)
2 26 (22) 34 (30) 1 (1) 2 (2) 63 (12.8)
3 32 (27) 2 (2) 0 0 34 (6.9)
4 9 (7) 1 (1) 0 0 10 (2.0)
5 2 (3) 0 0 0 2 (0.4)
Mean (95% CI) 2.04 (1.85–2.24) 1.32 (1.22–1.43) 0.90 (0.84–0.91) 1.00 (0.94–1.05) 1.27 (1.21–1.34) <10–10†

*χ2 test.
†1-Way analysis of variance.

Main Article

Page created: September 12, 2014
Page updated: September 12, 2014
Page reviewed: September 12, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external